MX2015012399A - Conjugado de peptidos inmunogenicos y metodo para inducir una respuesta a un anticuerpo terapeutico anti-influenza con los mismos. - Google Patents
Conjugado de peptidos inmunogenicos y metodo para inducir una respuesta a un anticuerpo terapeutico anti-influenza con los mismos.Info
- Publication number
- MX2015012399A MX2015012399A MX2015012399A MX2015012399A MX2015012399A MX 2015012399 A MX2015012399 A MX 2015012399A MX 2015012399 A MX2015012399 A MX 2015012399A MX 2015012399 A MX2015012399 A MX 2015012399A MX 2015012399 A MX2015012399 A MX 2015012399A
- Authority
- MX
- Mexico
- Prior art keywords
- influenza
- peptide conjugates
- immunogenic peptide
- antibody response
- immunogenic
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title abstract 8
- 239000000863 peptide conjugate Substances 0.000 title abstract 5
- 230000002163 immunogen Effects 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 230000005875 antibody response Effects 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title 1
- 101710154606 Hemagglutinin Proteins 0.000 abstract 5
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 5
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 5
- 101710176177 Protein A56 Proteins 0.000 abstract 5
- 239000000185 hemagglutinin Substances 0.000 abstract 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 abstract 2
- 229940098773 bovine serum albumin Drugs 0.000 abstract 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 230000034217 membrane fusion Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los conjugados de un péptido derivado de hemaglutinina de influenza inmunogénica descritos en la presente inducen una respuesta a anticuerpos terapéuticos específicos contra el virus de influenza. Los conjugados del péptido inmunogénico comprenden un segmento a partir del dominio de la región para inicio de fusión (FIR) de una proteína de hemaglutinina de influenza conjugada con una proteína potadora tal como hemocianina de caracol (KLH), albúmina de suero bovino (BSA), una proteína de hemaglutinina de influenza (HA), (es decir HA de longitud total), y lo semejante. Los conjugados del péptido inmnogénico descritos en la presente se pueden utilizar para tratar o prevenir una infección por influenza y para preparar anticuerpos terapéuticos influenza-específicos que interfieren con la fusión de la membrana de la célula hospedera del virus de influenza. Los conjugados del péptido se pueden formular en composiciones farmacéuticas útiles para el tratamiento o prevención de amplio espectro de las infecciones por influenza.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/828,988 US9649375B2 (en) | 2013-03-14 | 2013-03-14 | Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith |
| PCT/US2014/025968 WO2014160171A2 (en) | 2013-03-14 | 2014-03-13 | Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015012399A true MX2015012399A (es) | 2016-03-03 |
Family
ID=51527967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012399A MX2015012399A (es) | 2013-03-14 | 2014-03-13 | Conjugado de peptidos inmunogenicos y metodo para inducir una respuesta a un anticuerpo terapeutico anti-influenza con los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9649375B2 (es) |
| EP (1) | EP2970386A4 (es) |
| JP (1) | JP2016519061A (es) |
| CN (1) | CN105377876A (es) |
| AR (1) | AR095367A1 (es) |
| AU (2) | AU2014244071B2 (es) |
| CA (1) | CA2906519A1 (es) |
| EA (1) | EA030004B1 (es) |
| HK (1) | HK1222184A1 (es) |
| MX (1) | MX2015012399A (es) |
| TW (2) | TWI654205B (es) |
| WO (1) | WO2014160171A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018129624A1 (en) * | 2017-01-13 | 2018-07-19 | National Research Council Of Canada | Method of optimizing peptide immuno-epitope by glycosylation, optimized peptide thereof and its use for conjugate vaccines |
| WO2018237010A2 (en) | 2017-06-20 | 2018-12-27 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE |
| CN114516907B (zh) * | 2020-11-20 | 2024-03-29 | 中国科学技术大学 | 一种植物抗逆性相关基因atagl70及其编码蛋白与应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL98845A0 (en) | 1990-07-19 | 1992-07-15 | Merck & Co Inc | Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
| US5589174A (en) * | 1992-09-17 | 1996-12-31 | Takara Shuzo Co., Ltd. | Anti-human influenza virus antibody |
| US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| US7479285B1 (en) * | 1999-08-19 | 2009-01-20 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| US7189800B2 (en) * | 2001-03-27 | 2007-03-13 | Samuel Bogoch | Replikin peptides in rapid replication of glioma cells and in influenza epidemics |
| WO2003105782A2 (en) | 2002-06-17 | 2003-12-24 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Specificity grafting of a murine antibody onto a human framework |
| PT2261376E (pt) * | 2003-11-04 | 2013-09-23 | Univ Tulane | Método para prevenir a fusão vírus:células inibindo a função da região de iniciação de fusão em vírus de rna tendo proteínas do invólucro fusogénicas de membrana de classe i |
| SG2014012868A (en) * | 2005-10-18 | 2014-09-26 | Novavax Inc | Functional influenza virus like particles (vlps) |
| WO2007051036A2 (en) | 2005-10-26 | 2007-05-03 | Protelix, Inc. | Influenza combinatorial antigen vaccine |
| US8222204B2 (en) * | 2006-05-03 | 2012-07-17 | The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC | Influenza inhibiting compositions and methods |
| BRPI0711229A2 (pt) | 2006-05-31 | 2013-01-08 | Astellas Pharma Inc | anticorpo humanizado da osteopontina anti-humana, polinucleotÍdeo, vetor de expressço, cÉlula hospedeita, mÉtodo para produzir um anticorpo humanizado de osteopontina anti-humana, fÁrmaco terapÊutico, mÉtodo para prevenir ou tratar doenÇa autoimune e uso do anticorpo humanizado de oesteopontina anti-humana |
| KR101719135B1 (ko) * | 2007-06-25 | 2017-03-23 | 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 | 인플루엔자를 억제하는 조성물 및 방법 |
| EP2265646B1 (en) * | 2008-03-12 | 2016-01-27 | Her Majesty, The Queen in Right of Canada, as Represented by The Minister of Health | Reagents and methods for detecting influenza virus proteins |
| CA2787099A1 (en) | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
| WO2010124373A1 (en) | 2009-04-29 | 2010-11-04 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Influenza vaccine |
| WO2010124393A1 (en) | 2009-04-30 | 2010-11-04 | National Research Council Of Canada | Anticancer agent comprising a yatapoxvirus mutant and uses thereof |
| BRPI1012749B1 (pt) | 2009-05-11 | 2022-01-11 | Janssen Vaccines & Prevention B.V. | Anticorpo monoclonal humano, seu uso e seu método de produção, imunoconjugado, e composição farmacêutica |
| EP2528622A2 (en) * | 2010-01-26 | 2012-12-05 | The Regents of the University of Colorado | Influenza virus epitopes templated into double-stranded coiled coils and use thereof in immunization |
| MX346206B (es) | 2011-07-14 | 2017-03-09 | Crucell Holland Bv | Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b. |
-
2013
- 2013-03-14 US US13/828,988 patent/US9649375B2/en active Active
-
2014
- 2014-03-12 AR ARP140100906A patent/AR095367A1/es unknown
- 2014-03-13 CA CA2906519A patent/CA2906519A1/en not_active Abandoned
- 2014-03-13 WO PCT/US2014/025968 patent/WO2014160171A2/en active Application Filing
- 2014-03-13 EA EA201591747A patent/EA030004B1/ru not_active IP Right Cessation
- 2014-03-13 TW TW103109171A patent/TWI654205B/zh not_active IP Right Cessation
- 2014-03-13 JP JP2016502011A patent/JP2016519061A/ja active Pending
- 2014-03-13 TW TW107137751A patent/TW201925238A/zh unknown
- 2014-03-13 CN CN201480028403.5A patent/CN105377876A/zh active Pending
- 2014-03-13 MX MX2015012399A patent/MX2015012399A/es unknown
- 2014-03-13 AU AU2014244071A patent/AU2014244071B2/en not_active Ceased
- 2014-03-13 EP EP14776544.0A patent/EP2970386A4/en not_active Withdrawn
-
2016
- 2016-08-31 HK HK16110325.7A patent/HK1222184A1/zh unknown
-
2017
- 2017-05-10 US US15/591,386 patent/US10137194B2/en active Active - Reinstated
-
2018
- 2018-10-04 AU AU2018241125A patent/AU2018241125A1/en not_active Abandoned
- 2018-10-31 US US16/176,743 patent/US10537634B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA201591747A1 (ru) | 2016-02-29 |
| CA2906519A1 (en) | 2014-10-02 |
| CN105377876A (zh) | 2016-03-02 |
| US9649375B2 (en) | 2017-05-16 |
| EP2970386A2 (en) | 2016-01-20 |
| US20140271650A1 (en) | 2014-09-18 |
| EP2970386A4 (en) | 2016-10-26 |
| AU2014244071A1 (en) | 2015-10-29 |
| US20170258902A1 (en) | 2017-09-14 |
| US10537634B2 (en) | 2020-01-21 |
| TW201925238A (zh) | 2019-07-01 |
| TWI654205B (zh) | 2019-03-21 |
| US10137194B2 (en) | 2018-11-27 |
| HK1222184A1 (zh) | 2017-06-23 |
| TW201514208A (zh) | 2015-04-16 |
| WO2014160171A2 (en) | 2014-10-02 |
| AR095367A1 (es) | 2015-10-14 |
| AU2018241125A1 (en) | 2018-10-25 |
| EA030004B1 (ru) | 2018-06-29 |
| WO2014160171A3 (en) | 2015-04-23 |
| JP2016519061A (ja) | 2016-06-30 |
| US20190054168A1 (en) | 2019-02-21 |
| AU2014244071B2 (en) | 2018-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021007679A (es) | Anticuerpos humanos para hemaglutinina de influenza. | |
| PH12018502673A1 (en) | Anti-zika virus antibodies and methods of use | |
| EA201891186A1 (ru) | Антитела, нейтрализующие вирус иммунодефицита человека | |
| CR20210166A (es) | Composiciones y métodos para el tratamiento de infecciones virales | |
| PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
| EA201791675A1 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
| UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
| EA201391170A1 (ru) | Терапевтическое средство на основе дрожжей для лечения хронического гепатита b | |
| EA201000018A1 (ru) | Лиофилизированные лекарственные формы иммуноглобулинов и способы их получения | |
| EA201992784A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| MY192248A (en) | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage | |
| EA201992329A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| EA201892200A1 (ru) | Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге | |
| EA201992334A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| EA201790239A1 (ru) | Молекула-носитель для антигенов | |
| BR112017009790A2 (pt) | anticorpos direcionados ao anti-ang2 e métodos de uso | |
| MY185802A (en) | Antibody formulation | |
| EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
| EA201992782A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| CL2008002092A1 (es) | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. | |
| ZA202203681B (en) | Compositions and methods for the treatment of viral infections | |
| PH12014502352A1 (en) | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition | |
| WO2016061504A3 (en) | Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein | |
| MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. |